Regulation of plasminogen activation: A role for melanotransferrin (p97) in cell migration

Blood

Volumn 102, Issue 5, 2003, Pages 1723-1731

  Demeule, Michel ^b   Bertrand, Yanick ^b   Michaud Levesque, Jonathan ^b   Jodoin, Julie ^b   Rolland, Yannève ^b   Gabathuler, Reinhard ^b   Béliveau, Richard ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MELANOTRANSFERRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L235; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UROKINASE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CAPILLARY ENDOTHELIUM; CATTLE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

EID: 0042442134     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0166     Document Type: Article

References (43)

1. Brown JP, Hewick RM, Hellstrom I, Hellstrom KE, Doolittle RF, Dreyer WJ. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature. 1982;296:171-173.
2. Rose TM, Plowman GD, Teplow DB, Dreyer WJ, Hellstrom KE, Brown JP. Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A. 1986;83:1261-1265.
3. Brown JP, Woodbury RG, Hart CE, Hellstrom I, Hellstrom KE. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A. 1981;78:539-543.
4. Baker EN, Baker HM, Smith CA, et al. Human melanotransferrin (p97) has only one functional iron-binding site. FEBS Lett. 1992;298:215-218.
5. Alemany R., Vila MR, Franci C, Egea G, Real FX, Thomson TM. Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. J Cell Sci. 1993;104:1155-1162.
6. Food MR, Rothenberger S, Gabathuler R, Haidl ID, Reid G, Jefferies WA. Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. J Biol Chem. 1994;269:3034-3040.
7. Sekyere E, Richardson DR. The membrane-bound transferrin homologue melanotransferrin: roles other than iron transport? FEBS Lett. 2000;483:11-16.
8. Woodbury RG, Brown JP, Loop SM, Hellstrom KE, Hellstrom I. Analysis of normal neoplastic human tissues for the tumor-associated protein p97. Int J Cancer. 1981 27:145-149.
9. Woodbury RG, Brown JP, Yeh MY, Hellstrom I, Hellstrom KE. Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A. 1980;77:2183-2187.
10. Richardson DR. The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur J Biochem. 2000;267:1290-1298.
11. Jefferies WA, Food MR, Gabathuler R, et al. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 1996;712:122-126.
12. Kennard ML, Feldman H, Yamada T, Jefferies WA. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med. 1996;2:1230-1235.
13. Demeule M, Poirier J, Jodoin J, et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J Neurochem. 2002;83:924-933.
14. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1989;86:4828-4832.
15. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25-40.
16. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991;266:1926-1933.
17. Olson D, Pollanen J, Hoyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem. 1992;267:9129-9133.
18. Conese M, Nykjaer A, Petersen CM, et al. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol. 1995;131:1609-1622.
19. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997;16:2610-2620.
20. Neels JP, van den Berg BMM, Lookene A, et al. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem. 1999;274:31305-31311.
21. Cohen RL, Xi XP, Crowley CW, Lucas BK, Levinson AD, Shuman MA. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood. 1991;78:479-487.
22. Reiter LS, Kruithof EK, Cajot JF, Sordat B. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int J Cancer. 1993;53:444-450.
23. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25-40.
24. Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell. 2001;12:1467-1479,
25. Dehouck MP, Jolliet-Riant P, Bree F, Fruchart JC, Cecchelli R, Tillement JP. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem. 1992;58:1790-1797.
26. Johnsson B, Lofas S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 1991;198:268-277.
27. Kozyraki R, Fyfe J, Verroust PJ, et al. Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc Natl Acad Sci U S A. 2001;98:12491-12496.
28. Desrosiers RR, Bertrand Y, Nguyen QT, et al. Expression of melotransferrin isoforms in the human serum: relevance to Alzheimer's disease. Biochem J. In press.
29. Bu G, Rennke S. Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein. J Biol Chem. 1996;271:22218-2224.
30. Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaissa M, Spik G, Cecchelli R, Pierce A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem. 1999;274:7011-7007
31. Herz J, Strickland DK, LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779-784.
32. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
33. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
34. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428-2433.
35. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer. 1997;71:116-122.
36. Weaver A, Hussaini IM, Mazar A, Henkin J, Gonias SL. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem. 1997;272:14372-14379.
37. Tarui T, Mousumi M, Miles LA, Ruf W, Takeda Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem. 2002;277:33564-33570.
38. Sala R, Jefferies WA, Walker B, et al. The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo. Eur J Cell Biol. 2002;81:599-607.
39. Reijerkerk A, Voest EE, Gebbink MFBG. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer. 2000;36:1695-1705.
40. Liu CX, Li Y, Obermoeller-McCormick LM, Schwartz AL, Bu G. The putative tumor suppressor LRP1b, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem. 2001;276:28889-28896.
41. Li Y, Knisely JM, Lu W, et al. LDL receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J Biol Chem. 2002;277:42366-42371.
42. Gong Y, Kim SO, Felez J, Grella DK, Castellino FJ, Miles LA. Conversion of glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface. J Biol Chem. 2001;276:19078-19083.
43. Bass R, Fernandez AM, Ellis V. Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem. 2002;277:46845-46848.